Discrete event simulation has been used to explore different models of screening for diabetic retinopathy. Diabetic retinopathy is a common complication of diabetes and can cause blindness. The risk of blindness can be significantly reduced by screening and timely laser treatment. The simulation has been written in Pascal, using an extended version of Pascal_SIM, to explore the costs and benefits. The simulation models patients' disease progression and their screening, followed by treatment. The results shown are for patients with insulindependent diabetes.
Introduction
Discrete event simulation can model the progress of individuals through a system. This is useful for medical systems because the individuals can be given characteristics that influence their progress and thus have resource implications. It is also possible to describe constraints on resources.
Pascal_SIM is a set of routines in Pascal for discrete event simulations [1] which Davies and Davies [2] have extended for use in the medical field. One important feature is that patients may be scheduled to take part in more than one event simultaneously. This is particularly useful for a screening model because the simulation can describe the interaction between the patients progressing through the screening programme and their changing disease pathology.
In this project we modelled the development of eye disease in patients with insulin-dependent diabetes. Many diabetics suffer irreversible changes to their eyes and some become severely visually impaired. The problem usually starts with the development of background diabetic retinopathy, which affects approximately 59% of patients without retinopathy within the first four years of diagnosis [3] and most patients in due course. This condition is usually symptom free but may be detected by eye examination. Many patients go on to develop more severe retinal abnormalities: proliferative diabetic retinopathy (PDR) or diabetic macular edema (DME), or both.
-These conditions may not affect a patient's sight in their early stages. Loss of sight arising from these conditions may be slowed or arrested by laser treatment, if detected in time. The treatments, while having a proven beneficial effect [4] , are destructive and can harm sight. Most eye surgeons will not, therefore, give treatment until PDR or clinically significant macular edema, as defined by the Early Treatment Diabetic Retinopathy Study Research Group [4] , is detected.
Screening to detect and treat diabetic retinopathy already takes place in some locations in the UK, but there is no consistent screening policy. It may be done by general practitioners (GPs), dispensing opticians, diabetes physicians or ophthalmic surgeons. The different methods of screening include: ophthalmoscopy and photography, with and without pupil dilation. The accuracy of detection with these various personnel and techniques are different [5] affecting both the screening sensitivity (the proportion of correct detections of eye conditions in need of treatment) and the screening specificity (the proportion of correct identifications of eyes not in need of treatment). Clearly short screening intervals are likely to be more effective in picking up problems in time for treatment than long intervals.
Alternative Approaches
Simulation models can help evaluate the benefits and costs of the different modes of screening and the screening intervals. Some models have already been produced. Javitt et al. [6] have written several papers about their simulation, which is a time slicing technique describing a cohort of patients who are all assumed to start the disease at the same age. Dasbach et al. [7] used a spreadsheet approach that linked screening frequency with screening and treatment costs.
Davies and Davies [8] have discussed the relative merits of different approaches to modelling patient flows in the health systems. In summary, they preferred discrete event simulation because it could be both more flexible and more realistic. A further reason for developing their own model was that it could be adapted to answer questions of interest in the United Kingdom.
The Simulation Model
The Software
In the simulation, a patient's experiences over time are divided into discrete events, each of which is assumed to take no time. The simulation deals with events for all patients in time order. The extended version of Pascal SIM (XPSIM) was developed to allow entities to take more than one &dquo;route&dquo; through the system at once. This approach, which is particularly useful in the health context [2] , has been used for modelling patients with end-stage renal failure [9] and with coronary artery disease [10] . In using this approach for the screening model, screening can take place independently of the progression of the disease.
In this simulation, once treatable disease is detected by screening, the event &dquo;treatment&dquo; will change the projected time at which the simulated patient is to become visually impaired (usually to shorten it).
The detectable changes in patients' eyes are associated with changes in mortality. In XPSIM, death can be scheduled or rescheduled, without affecting the other activities until the time for death arrives. The other activities can then be descheduled.
Simulation Structure
Patients may develop PDR or DME, or some develop both. DME may lead to central vision loss whereas PDR may lead to more severe visual impairment. There are different treatments for each condition ; those with both conditions receive both types of treatment.
The current simulation model describes the progress of a cohort of patients, of different ages, starting the simulation with a diagnosis of diabetes. The time of death is scheduled for all active patients throughout the simulation run. Life expectancy is reduced as patients age and develop eye disease. The time to death is thus re-sampled at specific points during the simulation run. The simulation maintains a record of each patient including the state of their eye disease and the number of screens and treatments they have had. The simulation stops when all the patients have died.
Screening takes place independently of the disease progression but, on each occasion, the program accesses the patient record to determine the patient's eye condition. If the patient has not got the condition that the screening is trying to detect, then there is a probability of a false positive detection. Conversely, if the patient has got the condition then there is a probability that it will be missed (a false negative). The screening takes place in two stages: -the detection of background retinopathy and then -the detection of PDR or clinical DME.
Once background retinopathy has been detected, the screening interval may decrease or the screener or the screening method may change. Once PDR or clinical DME has been detected, then treatment is given. Each false positive is noted on a patient's record and screening is recommenced. When a condition is missed (false negative) then screening continues as if there were no treatable disease.
When treatment is given then the screening ceases, and the time to visual loss is rescheduled. Two branches of the simulation (the screening and the disease pathology) thus come together again. Figure 1 shows a simplified simulation structure in which patients develop and are screened for PDR but not DME. This demonstrates the interrelationship among the three paths in the simulation: the patient pathology, patient mortality and screening. Figure 2 shows the logic of each event in this simplified simulation. Figure 3 adds in the development and . > treatment for DME. The representation of this is more complicated because patients may get both PDR and DME and these can occur in either order.
Sampling
The data were derived from published papers. The values used and their sources are summarised in a paper by Davies [11] ..
Sampling Mortality
On the occurrence of certain events, a patient's date of death is re-sampled. For most of these, the new date of death replaces the old one. However, for patients with proliferative diabetic retinopathy (PDR) who subsequently get diabetic macular edema (DME), or vice versa, the mortality probabilities are assumed to be compounded. In the simulation, this means that when a new date of death is sampled, the date to be used is the nearest (in time) between the . existing and the newly sampled date. More details about the survival distributions are given in the paper by Davies [11] . 
Disease Progression
The probability of going from one treatment state to another is assumed to increase at adulthood (at around the age of 20 years) but remains the same ' from one year to the next after that. Progression to blindness may be interrupted by treatment. If treatment effectiveness is e%, then p, the probability of becoming blind, is reduced by p(1-e/100). At treatment, the time to blindness is re-sampled using the modified probability.
Sampling Probabilities
Each time screening takes place, the program accesses the patient record to see whether there is disease is present or not. If disease is present, the program samples for false negatives. If not, it samples for false positives.
Assumptions
The most fundamental assumption of using a discrete event simulation model is that disease can be separated into discrete stages. The stages chosen were as follows: those pertinent to a change in patient mortality; those at which treatment was needed; those defining the 'failure' that screening and treatment were trying to prevent; death.
These stages are not necessarily mutually exclusive or clear cut. Whilst the definition of death is usually certain, there may be some doubt as to whether and exactly when a treatment is needed or has failed. However, the choice of events which are assumed to cause changes in patient mortality are generally the most difficult to identify. In this model, the assumption that mortality could be related to discrete changes in the progression of the eye diseases was based on work done by Klein et al. [12] .
Some of the subsidiary assumptions incorporated in the model are as follows:
the likelihood of a false positive or negative result from any given screening episode is independent of that patient's previous history. the probability of dying is related to age and the degree of retinopathy, and where proliferative diabetic retinopathy and macular oedema coexist, their effect on mortality is cumulative. &dquo;patients&dquo; are not lost to follow-up but stay in the simulation until they die. screening takes place at the exact interval specified.
None of these subsidiary assumptions was fundamental to the model structure; they were made because they seemed to be appropriate simplifications.
.' Simulation Validation ' The simulation structure has been discussed with ophthalmic surgeons and diabetes physicians, and so we are confident that the structure is sound. To validate the assumptions and the data, we looked at publications concerned with disease prevalence and mortality.
One of the most extensive and reliable population studies of diabetic retinopathy is by a group in Wisconsin. They have written papers about the development and prevalence of eye disease within a population of diabetics. The simulation can provide estimates of the numbers of people with different eye , conditions within a population. These were compared with published values from Wisconsin papers [13, 14] .
The mortality of the simulation population was compared with studies of the mortality of a population of diabetics [15, 16, 17] . It was found possible to adjust the simulation parameters to get good fits in both respects. More details are given by Davies, Sullivan and Canning [18] .
Use of the Simulation
The program was used to simulate a cohort of a thousand patients with 10 replications for each scenario. The program stores information about the numbers of patients in each state (i.e. with PDR, DME etc.) and about the numbers of screening sessions, treatments and outpatient visits for each replication. The files of results are read into a spreadsheet for further analysis. The decision variables were: the sensitivity and specificity (as determined by the type of person doing the screening and the method of screening); the frequency of screening both before and after the detection of background retinopathy.
The results for each scenario were entered onto a different tab of a spreadsheet. One of the scenarios assumed that there was no screening and very little treatment given. It was thus possible to calculate for each of the other scenarios, the number of sight years saved by that screening policy.
The additional items of information entered on each tab were: the costs of each screening session (this depended on the screeners and the method of screening); the costs of the treatments; the costs of outpatient sessions after treatment. From this information it was possible to determine the cost to the health services per sight year saved.
Results

Sight Saved
In the results shown here, the screening specificity was kept constant between runs and the screening interval remained the same, both before and after the detection of background diabetic retinopathy. Figure 4 shows the trade-off between the screening sensitivity and screening interval. For example a 24 month interval at 100% sensitivity is equivalent to a 12 month interval at 70% sensitivity. Studies have shown [5] that some general practitioners and opticians in the United Kingdom may have screening sensitivities below 50% whereas diabetes physicians have sensitivities using ophthalmoscopy of over 90%.
A two year screening interval for physicians would thus appear to give a better outcome than a one year screening interval for general practitioners or physicians. Figure 5 shows the number of visits for different purposes under different screening intervals. The number of visits of each type changes very little for the different screening sensitivities but clearly varies considerably with the screening interval. The costs are thus associated with the different costs of the personnel, their screening methods and the number of visits.
Visits
Conclusion
The simulation provides a useful planning tool. It is able to provide information about the type of screening that is appropriate and at what cost for a large group of people. Bingley and Gale [19] showed that, in the Oxford Region, the incidence rate in the under 21 year age group is approximately 15.6 cases per 100,000 population. That implies that about 3,000 new cases are diagnosed in the United Kingdom each year. Most insulin-dependent diabetics get eye disease at some time and many go on to sightthreatening proliferative retinopathy or macular oedema.
Other models of this process have provided useful information [6, 7] . The discrete simulation structure, using XPSIM, in which the disease progression and screening structure operate independently, provides much more flexibility For example, in addition to simply changing the screening intervals and the screening sensitivities and specificities, as described in this paper, it would be possible to explore: -different screening policies for different groups of people; -different screening intervals for different stages of the disease; -variations in patient compliance with regular screening and outpatient visits.
The work is currently being used to look at patients with non-insulin dependent diabetes as well as those with insulin-dependent diabetes. This group of patients also develops eye disease, and they are much greater in number than the insulin dependent diabetics.
The simulation is currently being extended to describe a more realistic population of patients who, at the start of the simulation, are at different stages of the disease; new patients arise, at random, as time advances. This will provide a more comprehensive description of the progress of this group of patients over the next few years.
Screening problems arise in other fields: breast cancer, cervical cancer and glaucoma for example. The simulation approach can be extended to the evaluation of screening policies in these other areas.
